Atrial Fibrillation; Stroke Prevention Clinical Trial
Official title:
Stroke Prevention in Atrial Fibrillation Patients Between 2004 and 2020
| Verified date | January 2021 |
| Source | Jan Kochanowski University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Prevention of thromboembolic complications is an important part in the management of patients with atrial fibrillation (AF). European and American guidelines recommend the use of non-vitamin K antagonist oral anticoagulants (NOACs) over therapy with vitamin K antagonists (VKA) in most AF patients. The number of patients treated with NOACs has increased significantly during the last few years. In the primary randomized controlled trials leading to their approval, compared to warfarin, NOACs were shown to be either noninferior or superior for stroke prevention in AF, with similar or reduced rates of bleeding, especially intracranial haemorrhage. The aim of this study was to assess the frequency of oral anticoagulants using, espescially apixaban, dabigatran, and rivaroxaban, and the predictors of their prescription in a group of hospitalised patients with AF.
| Status | Recruiting |
| Enrollment | 10000 |
| Est. completion date | May 1, 2021 |
| Est. primary completion date | March 1, 2021 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - non-valvular atrial fibrillation Exclusion Criteria: - valvular atrial fibrillation - death during hospitalization |
| Country | Name | City | State |
|---|---|---|---|
| Poland | 1st Clinic of Cardiology and Electotherapy | Kielce | Grunwaldzka 45 |
| Poland | Iwona Gorczyca | Kielce |
| Lead Sponsor | Collaborator |
|---|---|
| Jan Kochanowski University |
Poland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | oral anticoagulant treatment | one year |